Form 4: Cytokinetics CEO Exercises Options, Adjusts Holdings

Cytokinetics' President and CEO, Robert I. Blum, exercised stock options and adjusted his beneficial ownership of common stock through pre-planned transactions.

Summary

• Robert I. Blum, President & CEO and Director of Cytokinetics Inc. (CYTK), engaged in several transactions involving the company's common stock on December 22, 2025.
• Blum acquired 54,727 shares of common stock by exercising non-qualified stock options at an exercise price of $6.67 per share.
• Concurrently, 30,426 shares were disposed of at a price of $68.18 per share to cover the exercise price and tax withholding obligations related to the non-qualified stock option exercise.
• An additional 16,506 shares of common stock were acquired through the exercise of incentive stock options, also at an exercise price of $6.67 per share.
• Following these transactions, Blum directly beneficially owns 391,009 shares of common stock.
• Blum also indirectly beneficially owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While there's a disposition of shares, it's primarily for tax and exercise costs, which is a common practice. The underlying action is the exercise of options, indicating the insider is realizing value from their equity compensation, often seen as a positive sign of value creation over time, especially when done under a 10b5-1 plan.

Positives

• The CEO exercised a significant number of stock options (71,233 shares total), indicating a long-term commitment and belief in the company's value at the time the options were granted.
• The exercise price of $6.67 is significantly lower than the disposition price of $68.18, suggesting a substantial in-the-money value for the options.

Negatives

• A portion of the acquired shares (30,426 shares) was immediately sold to cover the exercise price and tax withholding obligations, resulting in a net reduction of direct beneficial ownership from the initial option exercise amount.

Risks

• While not a direct risk from this filing, the disposition of shares, even for tax purposes, reduces the insider's direct equity stake, which could be interpreted by some as a slight reduction in direct alignment with shareholder interests, though this is a common practice.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This routine insider transaction report does not provide specific details to analyze broader industry trends or competitive positioning. It reflects standard equity compensation practices for executives.

Related Party Transactions

• Robert I. Blum indirectly beneficially owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

Stakeholder Impact

• Shareholders may view the exercise of options by the CEO as a positive signal regarding the long-term value of the company, even with the associated 'sell to cover' transaction.
• The transactions are part of standard executive compensation practices and do not indicate a significant shift in company strategy or operations impacting employees, customers, suppliers, or creditors.

Next Steps

• This filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the reported transactions.

Key Dates

Keywords

Cytokinetics, CYTK, Robert I. Blum, Insider Trading, Form 4, Stock Options, CEO, Beneficial Ownership, Equity Compensation, Rule 10b5-1